Targeting Disease with B-Tech

ILiAD's B-Tech program integrates validated proprietary technology to develop therapeutics for the prevention and treatment of disease. BPZE1 is the most advanced ILiAD clinical candidate developed using B-Tech.

In addition to BPZE1, the B-Tech program includes the B-Tech Vector platform for delivering a range of pathogenic and immuno-oncology antigens to mucosal tissue, asthma and allergy therapeutic vaccine candidates, disease research on B. Pertussis subclinical colonizing infections, and the wholly-owned subsidiary BioLyo Technologies that focuses on live biological manufacturing process development.

---